Subscribe to RSS
DOI: 10.1055/a-0863-5779
Serum Prostate-Specific Antigen Level in Women With Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis
Publication History
received 26 March 2018
Publication Date:
25 April 2019 (online)
![](https://www.thieme-connect.de/media/hmr/201904/lookinside/thumbnails/2018-03-0117_10-1055-a-0863-5779-1.jpg)
Abstract
We undertook a comprehensive search of all published original articles evaluating the diagnostic value of prostate-specific antigen (PSA) for the detection of polycystic ovary syndrome (PCOS). Finally, 25 studies with a total of 1865 participants (1104 cases and 761 controls) met the inclusion criteria. Mean serum PSA levels were significantly higher in PCOS women compared to healthy women [Standardized mean difference (SMD)=1.73 ng/ml, 95% CI=1.22 to 2.25, p<0.001]. Only 5 studies reported accuracy indicators and were included in the bivariate random-effects model; with a total of 509 samples that included 332 (65.22%) confirmed PCOS women. The sensitivity of serum PSA for the diagnosis of PCOS varied between 66.3 and 90.6%, and, the specificity ranged from 62.5–86.7%. Meta-analysis revealed a pooled sensitivity of 72.3% (95% CI 67.1–77.00%) and specificity of 74.6% (95% CI 67.5–80.8%) with an area under the summary ROC curve equal to 0.82 (95% CI 0.75–0.83). The summary estimates were 2.92 (95% CI 1.98–4.31) for positive LR and 0.37 (95% CI 0.26–0.51) for negative LR. The pooled estimate of diagnostic odds ratio (DOR) of serum PSA was 9.01 (95% CI 4.35–18.64). Considering the methodological weaknesses existed in studies, lack of sufficient data regarding the accuracy indicators, and the complexity of the exact pathophysiology of PSA secretion in women, the precise position of PSA, as a diagnostic test for the detection of PCOS, in clinical practice is undetermined, and further studies are still needed.
Supplementary Material
- for this article is available online at http://www.thieme-connect.de/products.
- Supplementary Material
-
References
- 1 Azziz R, Carmina E, Dewailly D. et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: The complete task force report. Fertil Steril 2009; 91: 456-488
- 2 Di Fede G, Mansueto P, Pepe I. et al. High prevalence of polycystic ovary syndrome in women with mild hirsutism and no other significant clinical symptoms. Fertil Steril 2010; 94: 194-197
- 3 Norman RJ, Dewailly D, Legro RS. et al. Polycystic ovary syndrome. Lancet 2007; 370: 685-697
- 4 Martin KA, Chang RJ, Ehrmann DA. et al. Evaluation and treatment of hirsutism in premenopausal women: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2008; 93: 1105-1120
- 5 Rosenfield RL. Clinical practice. Hirsutism. N Engl J Med 2005; 353: 2578-2588
- 6 Souter I, Sanchez LA, Perez M. et al. The prevalence of androgen excess among patients with minimal unwanted hair growth. Am J Obstetr Gynecol 2004; 191: 1914-1920
- 7 Mangelsdorf S, Otberg N, Maibach HI. et al Ethnic variation in vellus hair follicle size and distribution. Skin Pharmacol Physiol 2006; 19: 159-167
- 8 Amiri M, Ramezani Tehrani F, Nahidi F. et al. Association between biochemical hyperandrogenism parameters and Ferriman–Gallwey score in patients with polycystic ovary syndrome: a systematic review and meta-regression analysis. Clin Endocrinol 2017; 87: 217-230
- 9 Asunción M, Calvo RM, San Millàn JL. et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab 2000; 85: 2434-2438
- 10 Witchel SF, Oberfield S, Rosenfield RL. et al. The diagnosis of polycystic ovary syndrome during adolescence. Horm Res Paediatr 2015; 83: 376-389
- 11 Goodman NF, Cobin RH, Futterweit W. et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and androgen excess and PCOS society disease state clinical review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome-part 1. Endocr Pract 2015; 21: 1291-1300
- 12 Rosner W, Vesper H. Toward excellence in testosterone testing: a consensus statement. J Cli Endocrinol Metab 2010; 95: 4542-4548
- 13 Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer 2008; 8: 268-278
- 14 Wang M, Valenzuela L, Murphy G. et al. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-163
- 15 Diamandis E, Yu H. New biological functions of prostate-specific antigen?. J Clin Endocrinol Metab 1995; 80: 1515-1517
- 16 Yu H, Diamandis EP, Sutherland DJ. Immunoreactive prostate-specific antigen levels in female and male breast tumors and its association with steroid hormone receptors and patient age. Clin Biochem 1994; 27: 75-79
- 17 Burelli A, Cionini R, Rinaldi E. et al. Serum PSA levels are not affected by the menstrual cycle or the menopause, but are increased in subjects with polycystic ovary syndrome. J Endocrinol Invest 2006; 29: 308-312
- 18 Diamandis EP, Stanczyk FZ, Wheeler S. et al. Serum complexed and free prostate-specific antigen (PSA) for the diagnosis of the polycystic ovarian syndrome (PCOS). Clin Chem Lab Med 2017; 55: 1789-1797
- 19 Obiezu CV, Scorilas A, Magklara A. et al. Prostate-specific antigen and human glandular kallikrein 2 are markedly elevated in urine of patients with polycystic ovary syndrome. J Clin Endocrinol Metab 2001; 86: 1558-1561
- 20 Bahceci M, Bilge M, Tuzcu A. et al. Serum prostate specific antigen levels in women with polycystic ovary syndrome and the effect of flutamide+ desogestrel/ethinyl estradiol combination. J Endocrinol Invest 2004; 27: 353-356
- 21 Cebeci F, Onsun N, Ummetoglu O. et al. Serum prostatic specific antigen levels in women with hirsutism/Hirsutizmli kadinlarda serum prostatik spesifik antijen duzeyleri. Arch Turk Dermatol Venerol 2009; DOI: 104-107.
- 22 Güllü S, Emral R, Asik M. et al. Diagnostic value of prostatic specific antigen in hirsute women. J Endocrinol Inves 2003; 26: 1198-1202
- 23 Guzelmeric K, Seker N, Unal O. et al. High serum prostate-specific antigen concentrations in hirsute women do not decrease with treatment by the combination of spironolactone and the contraceptive pill. Gynecol Endocrinol 2004; 19: 190-195
- 24 Kocak M. Serum levels of prostate-specific antigen and androgens after nasal administration of a gonadotropin releasing hormone-agonist in hirsute women. Gynecol Endocrinol 2004; 18: 179-185
- 25 Tokmak A, Bodur S, Erkilinc S. et al. The value of prostate-specific antigen in diagnosis of polycystic ovarian syndrome in adolescent girls. J Pediatr Adolesc Gynecol 2018; 31: 263-269
- 26 Vural B, Özkan S, Bodur H. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?. J Obstetr Gynaecol Res 2007; 33: 166-173
- 27 Escobar-Morreale HcF, Àvila S, Sancho J. Serum prostate-specific antigen concentrations are not useful for monitoring the treatment of hirsutism with oral contraceptive pills. J Clin Endocrinol Metab 2000; 85: 2488-2492
- 28 Escobar-Morreale HcF, Serrano-Gotarredona Jn, Avila S. et al. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998; 83: 2580-2584
- 29 Riesco O, Blaustein C, Scaglia J. et al. Niveles circulantes de Antígeno Específico de Próstata (PSA) en mujeres con hirsutismo idiopático (HI). RAEM 2005; 42: 109
- 30 Negri C, Tosi F, Dorizzi R. et al. Antiandrogen drugs lower serum prostate-specific antigen (PSA) levels in hirsute subjects: Evidence that serum PSA is a marker of androgen action in women. J Clin EndocrinolMetab 2000; 85: 81-84
- 31 Camacho F, López-Elorza F, Rodríguez-Rey E. et al. Prostate-specific antigen levels as hyperandrogenism marker in women. J Eur Acad Dermatol Venereol 2009; 23: 221-223
- 32 Panigrahy R, Singh B, Pattnaik TK. et al. Role of insulin sensitising agents in altering PSA level in PCOS. Int J Reprod Contracep. Obstet Gynecol 2017; 6: 4986-4989
- 33 Sharaf AE, El Mongy NN, Fawzy MM. et al. Prostate-specific antigen as a diagnostic marker in female hyperandrogenism. J Egypt Women Dermatol Soc 2013; 10: 58-62
- 34 Metawie MAH, El Sarafy T, El-Kattan S. et al. Serum-prostatic specific antigen level as a promising marker in infertile women with polycystic ovarian disease. Middle East Fertil Soc J 2008; 13: 28-32
- 35 Wasan I, Raya S, Widad A. Serum prostate specific antigen level in women with polycystic ovary syndrome. J Fac Med Baghdad 2016; 58: 136-139
- 36 Ükinç K, Ersoz HO, Erem C, Hacihasanoglu AB. Diagnostic value of prostate-specific antigen (PSA) and free prostate specific antigen (fPSA) in women with ovulatory and anovulatory polycystic ovary syndrome. Endocrine 2009; 35: 123-129
- 37 Rudnicka E, Radowicki S, Suchta K. Prostate specific antigen (PSA) in diagnosis of polycystic ovarian syndrome–a new insight. Gynecol Endocrinol 2016; 32: 931-935
- 38 Mardanian F, Heidari N. Diagnostic value of prostate-specific antigen in women with polycystic ovary syndrome. J Res Med Sci 2011; 16: 999
- 39 Mohajir Hussein AM, Hussein E, Eltom A. Assessment of serum Prostate specific antigen (PSA) level among Sudanese women with polycystic ovarian syndrome In Khartoum state. Sch J Appl. Med Sci 2017; 5: 1288-1296
- 40 Wang G, Xu R, Zhang Z. Increased level of prostate-specific antigen: a diagnostic marker of hyperandrogenism women. Zhonghua nan ke xue: Natl J Androl 2009; 15: 1028-1030
- 41 Galadari I, Al-Mazroei M, Alkaabi J. Prostatic-specific antigen and idiopathic hirsutism in females. Int J Dermatol 2004; 43: 275-277
- 42 Bili E, Dampala K, Iakovou I. et al. The combination of ovarian volume and outline has better diagnostic accuracy than prostate-specific antigen (PSA) concentrations in women with polycystic ovarian syndrome (PCOs). Eur J Obstet Gynecol Reprod Biol 2014; 179: 32-35
- 43 Melegos DN, Yu H, Ashok M. et al. Prostate-specific antigen in female serum, a potential new marker of androgen excess. J Clin Endocrinol Metab 1997; 82: 777-780
- 44 Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997; 158: 1606-1609
- 45 Borchert G, Melegos D, Tomlinson G. et al. Molecular forms of prostate-specific antigen in the serum of women with benign and malignant breast diseases. Br J Cancer 1997; 76: 1087-1094
- 46 Clements J, Mukhtar A. Glandular kallikreins and prostate-specific antigen are expressed in the human endometrium. J Clin Endocrinol Metab 1994; 78: 1536-1539
- 47 Wernert N, Albrech M, Sesterhenn I. et al. The 'female prostate': Location, morphology, immunohistochemical characteristics and significance. Eur Urol 1992; 22: 64-69
- 48 Aksoy H, Akçay F, Umudum Z. et al. Changes of PSA concentrations in serum and saliva of healthy women during the menstrual cycle. Ann Clin Lab Sci 2002; 32: 31-36
- 49 Lambert-Messerlian GM, Canick JA, Melegos DN. et al. Increased concentrations of prostate-specific antigen in maternal serum from pregnancies affected by fetal Down syndrome. Clin Chem 1998; 44: 205-208
- 50 Stemp M, Roberts P, McClements A. et al. Serum concentrations of the biomarkers CA125, CA15-3, PSA and PAPP-A in early pregnancy. J Reprod Biotechnol Fertil 2016; 5: 2058915816672102
- 51 Wald N, Hackshaw A, Diamandis E. et al. Maternal serum prostatespecific antigen and Down syndrome in the first and second trimesters of pregnancy. Prenat Diagnos 1999; 19: 674-676
- 52 Yu H, Diamandis EP. Prostate-specific antigen immunoreactivity in amniotic fluid. Clin Chem 1995; 41: 54-58
- 53 Yu H, Diamandis EP. Prostate-specific antigen in milk of lactating women. Clin Chem 1995; 41: 54-58
- 54 Diamandis EP, Yu H. Nonprostatic sources of prostate-specific antigen. Urol Clin North Am 1997; 24: 275-282
- 55 Cleutjens KB, van der Korput HA, van Eekelen CC. et al. An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter. Mol Endocrinol 1997; 11: 148-161
- 56 Shan J-D, Porvari K, Ruokonen M. et al. Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate-specific glandular kallikrein. Endocrinology 1997; 138: 3764-3770
- 57 Zarghami N, Grass L, Diamandis E. Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cance 1997; 75: 579-588
- 58 Lilja H. Structure, function, and regulation of the enzyme activity of prostate-specific antigen. World J Urol 1993; 11: 188-191
- 59 Levesque M, Hu H, Diamandis EP. et al. Prostate-Specific antigen expression by various tumors. J Clin Lab Anal 1995; 9: 123-128
- 60 Yu H, Diamandis EP, Levesque M. et al. Expression of the prostate-specific antigen gene by a primary ovarian carcinoma. Cancer Res 1995; 55: 1603-1606
- 61 Burger HG. Androgen production in women. Fertility and Sterility 2002; 77: 3-5
- 62 Escobar-Morreale HF, Serrano-Gotarredona J, Avila S. et al. The increased circulating prostate-specific antigen concentrations in women with hirsutism do not respond to acute changes in adrenal or ovarian function. J Clin Endocrinol Metab 1998; 83: 2580-2584
- 63 Manetti L, Lupi I, Genovesi M. et al. Serum prostate-specific antigen concentration is increased in acromegalic women. J Endocrinol Invest 2004; 27: 643-647
- 64 Diamandis EP, Eklund E, Muytjens C. et al. Effect of age on serum prostate-specific antigen in women. Clin Chem Lab Med 2017; 55: e271-e272
- 65 Giai M, Yu H, Roagna R. et al. Prostate-specific antigen in serum of women with breast cancer. Br J Cancer 1995; 72: 728
- 66 Yu H, Diamandis EP. Prostate Cancer: Measurement of serum prostate specific antigen levels in women and in prostatectomized men with an ultrasensitive immunoassay technique. J Urol 1995; 153: 1004-1008
- 67 Yu H, Diamandis EP, Levesque M. et al. Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 1996; 40: 171-178
- 68 Azziz R, Carmina E, Dewailly D. et al. Criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an androgen excess society guideline. J Clin Endocrinol Metab 2006; 91: 4237-4245
- 69 Johnson T, Kaplan L, Ouyang P. et al. National Institutes of Health evidence-based methodology workshop on polycystic ovary syndrome (PCOS). NIH EbMW Report Bethesda, National Institutes of Health 2012; 1: 1-14
- 70 Bock JL, Klee GG. How Sensitive Is a Prostate-Specific Antigen Measurement?: How Sensitive Does It Need to Be?. Arch Pathol Lab Med 2004; 128: 341-343
- 71 McDermed JE, Sanders R, Fait S. et al. Nucleic acid detection immunoassay for prostate-specific antigen based on immuno-PCR methodology. Clin Chem 2012; 58: 732-740
- 72 Wilson DH, Hanlon DW, Provuncher GK. et al. Fifth-generation digital immunoassay for prostate-specific antigen by single molecule array technology. Clin Chem 2011; 57: 1712-1721
- 73 Zarghami N, Grass L, Sauter ER. et al. Prostate-specific antigen in serum during the menstrual cycle. Clin Chem 1997; 43: 1862-1867